Among HER2-aberrant NSCLC, HER2 mutation mainly occurs in female no-smokers, performing similar clinicopathological characteristics to EGFR mutation, and acquired HER2 amplification is a mechanism of resistance to EGFR-TKIs (7). Here, ERBB2 is linked to non-small cell lung carcinoma.